Safety and Immunogenicity of pDNA HIV Vaccines (p24CE1/2 and p55^gag) with IL-12 Adjuvant in Healthy Adults

Phase 1, randomised trial of p24CE DNA vaccine and p55Gag plasmid DNA vaccine in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness at Month 6, Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration at Month 6 and 11 more. Started Oct 2017; status: completed.